RESEARCH ARTICLE

Prognostic significance of APACHE II score and plasma suPAR in Chinese patients with sepsis: a prospective observational study

Xuan Liu, Yong Shen, Zhihua Li, Aihua Fei, Hairong Wang, Qinmin Ge and Shuming Pan*

Abstract

Background: Timely risk stratification is the key strategy to improve prognosis of patients with sepsis. Previous study has proposed to develop a powerful risk assessment rule by the combination of Acute Physiology and Chronic Health Evaluation II (APACHE II) score and plasma soluble urokinase plasminogen activator receptor (suPAR). That reaffirmation of suPAR as a prognostic marker in Chinese patients with severe sepsis is the aim of the study.

Methods: A total of 137 consecutive Chinese patients with sepsis were enrolled in a prospective study cohort. Demographic and clinical characteristics, conventional risk factors and important laboratory data were prospectively recorded. Sequential plasma suPAR concentrations were measured by an enzymeimmunoabsorbent assay on days 1, 3, and 7 after admission to the intensive care unit (ICU). Receiver operating characteristic (ROC) curves and Cox regression analysis were used to examine the performance of suPAR in developing a rule for risk stratification.

Results: The results showed that plasma suPAR concentrations remained relatively stable within survivors and non-survivors during the first week of disease course. Regression analysis indicated that APACHE II ≥15 and suPAR ≥10.82 ng/mL were independently associated with unfavorable outcome. With the above cutoffs of APACHE II and suPAR, strata of disease severity were determined. The mortality of each stratum differed significantly from the others.

Conclusions: Combination of APACHE II score and suPAR may supply the powerful prognostic utility for the mortality of sepsis.

Keywords: Sepsis, Risk stratification, Soluble urokinase plasminogen activator receptor (suPAR), Acute Physiology and Chronic Health Evaluation II (APACHE II)

Background

The incidence of sepsis in adults has been increasing, with severe sepsis and septic shock remaining among the major causes of death worldwide [1]. Despite the mortality is on a declining trend in recent years [2], low awareness, late recognition, and improper treatment are still common [3].

One of the fundamental principles for the appropriate management of sepsis is timely discrimination of the patients at high risk for death [4]. This is generally dependent on the application of score systems and plasma biomarkers. Although the well-recognized score is the Acute Physiology and Chronic Health Evaluation II (APACHE II), APACHE II score has some potential pitfalls that may lead to inaccurate evaluation. Take young patients with severe sepsis but without chronic organ dysfunction for instance, the APACHE II score may be relatively low despite the risk for an unfavorable outcome is high [5].

Although various biological markers are widely explored [6–9], only a few have been applied in the clinical practice. The soluble urokinase plasminogen activator receptor (suPAR), which exists in three forms (I-III, II-III and I), is regarded as a novel biomarker of immune system activation [10]. Urokinase plasminogen activator...
receptor (uPAR) is embedded in the cell membranes of various immunologically active cells and, with its ligand, urokinase plasminogen activator (uPA), takes part in a range of immunologic activities [11]. Upon inflammatory stimulation, uPAR is cleaved from the cell surface by proteases into the soluble form of the receptor-suPAR—which can be assessed in blood, urine, bronchoalveolar lavage, and cerebrospinal fluid [12, 13]. Recent studies have revealed that suPAR may have the ability to predict the mortality of sepsis [14–17]. It is noteworthy that Giamarellos-Bourboulis et al. have proposed a new prognostic rule for predicting the outcome of sepsis by APACHE II score and suPAR [5].

The primary purpose of the present study was to further reaffirm the prediction rule for the mortality in Chinese patients with sepsis by combining APACHE II score and plasma suPAR concentrations.

Methods
Study design
This prospective trial involved consecutive Chinese patients with sepsis presenting to the intensive care unit (ICU) of the Department of Emergency, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, from March 2013 to February 2015.

For each patient with suspected infection, a complete diagnostic work-up was performed. The work-up comprised demographic and clinical characteristics, conventional risk factors, and important laboratory data including blood routine examination, microbiological culturing, chest x-ray, and chest or abdominal computed tomography if necessary. Broad spectrum antimicrobial treatment was used within 1 h from the recognition of the septic status.

Patients were eligible if they met the inclusion criteria: (1) age of at least 18 years; (2) sepsis due to one of the following infections: community acquired pneumonia, hospital acquired pneumonia, ventilator-associated pneumonia, acute pyelonephritis, intra-abdominal infection, or primary bacteremia; and (3) blood sampling within 24 h from the presentation of signs of sepsis. Patients affected by advanced cancer or terminal patients with other pathologies were excluded.

All eligible patients were further classified according to standard definitions of sepsis, severe sepsis, and septic shock [18]. More specifically, sepsis was defined as the presence of suspected or confirmed infection together with two or more criteria for a systemic inflammatory response; severe sepsis was defined as sepsis with sepsis-induced organ dysfunction, hypotension or hypoperfusion; septic shock was defined as refractory hypotension or hypoperfusion despite sufficient fluid resuscitation.

Blood measurements
Venous blood (3 mL) was collected from patients presenting to the ICU (day 1) and repeated on the following day 3 and day 7 after admission. Whole blood was drawn into a centrifuge tube containing EDTA anticoagulant. After centrifugation at 3,000 g for 10 min at 4 °C, plasma samples were kept frozen at −80 °C until assayed. suPAR was determined in duplicate by a commercial double monoclonal antibody sandwich enzyme immunoassay (suPARnostic® Standard kit; ViroGates A/S, Birkerød, Denmark) in accordance with the instructions of the manufacturer. Every 45 blood samples can be measured within about 4 h. The linearity of this assay is comprised between 2.0 and 15.6 ng/mL, and the total imprecision, expressed as coefficient of variation (CV %), ranges from 2.3 to 6.0 %.

Study outcomes
Patients who survived were further followed up by telephone calls. The unfavorable outcome of the study was defined as death from any cause within 28 days after admission to the ICU.

Statistical analysis
Continuous variables were presented as mean values ± standard deviation (SD) or median with interquartile ranges (IQR), while categorical variables were expressed as percentages. The statistical significance of intergroup differences was compared through unpaired Student's t-test or Mann–Whitney U test for continuous variables and through Pearson’s χ² test for categorical variables.

The following steps were performed to establish a risk stratification rule: First, receiver operating characteristic (ROC) analysis was conducted with baseline levels of APACHE II score and suPAR to determine the prediction sensitivity and specificity of the variables. Second, we used univariate and multivariate Cox regression analyses to calculate hazard ratios (HR) with 95 % confidence intervals (CIs). Third, strata of disease severity were established using the cutoffs of APACHE II score and suPAR. Odds ratios (OR) and 95 % CIs for risk prediction within each stratum were assessed using Mantel and Haenszel statistics. Fourth, mortalities between strata were estimated using the log-rank test.

A two-sided P value < 0.05 was considered statistically significant. All analyses were performed by the IBM SPSS Statistics software version 19.0 (SPSS, Chicago, IL, USA).

Results
Baseline characteristics of the study population
A total of 137 consecutive patients (51.09 % men; mean age, 69.53 ± 9.28 years) were eligible for enrollment in the study. After the initial evaluation performed in the
ICU, patients were divided into three groups according to the disease severity: group 1, patients with sepsis (n = 56); group 2, those with severe sepsis (n = 49); and group 3, those with septic shock (n = 32). The baseline clinical and laboratory characteristics of the patients are elaborated in Table 1. The most common locations of infection were lung and urinary tract, and the distribution of locations was similar among the three groups. The commonest isolated pathogens from the study cohort were Gram-negative microorganisms with a predominance of *Escherichia coli*, and blood cultures were positive in 43.80 % of all patients. There was not any difference in pathogen strains among the different groups (Table 1).

There were no significantly statistical differences in patients with sepsis compared to those in severe sepsis or septic shock for gender or age. Patients with severe sepsis or septic shock tended to have higher baseline levels

| Table 1 Baseline clinical and laboratory characteristics of the study subjects |
|---------------------------------|----------------|----------------|----------------|----------------|
| Characteristics                | Sepsis         | Severe sepsis  | Septic shock   | P value        |
| Demographics and underlying conditions |                 |               |                |                |
| Number of patients             | 56             | 49            | 32            |                |
| Males, no. (%)                 | 29(51.79 %)    | 27(55.10 %)   | 14(43.75 %)   | 0.418          |
| Age (years), mean ± SD         | 68.04 ± 9.36   | 71.39 ± 8.85  | 69.16 ± 9.73  | 0.246          |
| COPD, no (%)                   | 20(35.71 %)    | 23(46.94 %)   | 17(53.13 %)   | 0.273          |
| Hypertension, no (%)           | 9(16.07 %)     | 9(18.37 %)    | 7(21.88 %)    | 0.381          |
| Diabetes mellitus, no (%)      | 9(16.07 %)     | 9(18.37 %)    | 7(21.88 %)    | 0.381          |
| Baseline parameters, mean ± SD |                 |               |                |                |
| APACHE II score                | 9.87 ± 3.12    | 12.50 ± 4.75  | 18.34 ± 6.09  | 0.001**        |
| SOFA score                     | 5.26 ± 2.09    | 7.83 ± 2.53   | 11.42 ± 3.74  | 0.002**        |
| SuPAR (ng/mL)                  | 6.58 ± 3.17    | 8.62 ± 4.80   | 15.97 ± 5.44  | 0.001**        |
| PCT (ng/mL)                    | 6.14 ± 3.54    | 11.05 ± 4.60  | 27.69 ± 7.28  | <0.001**       |
| White blood cell count (10⁹/L) | 11.96 ± 2.866  | 18.26 ± 3.98  | 26.67 ± 7.04  | 0.037**        |
| Lactic acid (mmol/L)           | 1.75 ± 1.16    | 3.27 ± 1.48   | 6.03 ± 3.82   | 0.012*         |
| BUN (mmol/L)                   | 6.42 ± 3.85    | 9.05 ± 4.13   | 11.91 ± 9.39  | 0.017*         |
| Scr (μmol/L)                   | 70.32 ± 19.56  | 103.59 ± 31.07| 154.08 ± 40.87| 0.021*         |
| ALT (U/L)                      | 31.23 ± 10.27  | 45.62 ± 16.44 | 153.89 ± 48.01| 0.013*         |
| AST (U/L)                      | 32.95 ± 11.02  | 60.38 ± 21.37 | 196.35 ± 65.29| 0.009**        |
| Bilirubin (mg/dL)              | 14.60 ± 8.03   | 16.23 ± 9.15  | 20.01 ± 9.66  | 0.694          |
| Platelet (10⁹/L)               | 154.19 ± 71.52 | 134.08 ± 75.17| 127.60 ± 65.95| 0.741          |
| Plasma glucose (mmol/L)        | 7.25 ± 4.89    | 8.35 ± 5.18   | 10.02 ± 7.11  | 0.389          |
| Hemoglobin (g/L)               | 109.84 ± 33.14 | 117.08 ± 20.49| 118.05 ± 20.65| 0.436          |
| Pathogen strains, no (%)       | 0.058          |               |                |                |
| *Escherichia coli*             | 6(10.71 %)     | 6(12.24 %)    | 5 (15.63 %)   | -              |
| *Klebsiella pneumonia*         | 5(9.39 %)      | 4(18.16 %)    | 4 (12.50 %)   | -              |
| *Pseudomonas aeruginosa*       | 2(3.57 %)      | 3(6.12 %)     | 3 (9.38 %)    | -              |
| *Acinetobacter baumannii*      | 3(5.36 %)      | 4(18.16 %)    | 3 (9.38 %)    | -              |
| *Other Gram-negative bacteria* | 2(3.57 %)      | 2(4.08 %)     | 1(3.13 %)     | -              |
| *Staphylococcus aureus*        | 1(1.79 %)      | 2(4.08 %)     | 2 (6.25 %)    | -              |
| *Enterococcus spp*             | 1(1.79 %)      | 1(2.04 %)     | 0(0.00 %)     | -              |
| Site of infection, no (%)      | 0.713          |               |                |                |
| Lung                           | 18(32.14 %)    | 23(46.94 %)   | 15(46.88 %)   | -              |
| Urinary tract                  | 15(26.79 %)    | 13(26.53 %)   | 8(25.00 %)    | -              |
| Abdomen                        | 11(19.64 %)    | 7(14.29 %)    | 6(18.75 %)    | -              |
| Other                          | 12(21.43 %)    | 6(12.24 %)    | 3 (9.38 %)    | -              |
| Intervention, no (%)           |                 |               |                |                |
| Mechanical ventilation         | 3(5.36 %)      | 4(18.16 %)    | 12(37.50 %)   | 0.005**        |
| CRRT                           | 2(3.57 %)      | 6(12.24 %)    | 15 (46.88 %)  | 0.004**        |
| Vasopressor usage              | 0(0.00 %)      | 4(18.16 %)    | 13(40.63 %)   | 0.001**        |
| Study outcome, no (%)          | 3(5.37 %)      | 4(18.16 %)    | 14 (43.75 %)  | 0.001**        |

Abbreviations: COPD chronic obstructive pulmonary disorder, APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA sequential organ failure assessment, suPAR soluble urokinase plasminogen activator receptor, PCT procalcitonin, BUN blood urea nitrogen, Scr serum creatinine, ALT alanine transaminase, AST aspartate transaminase, CRRT continuous renal replacement therapy

Data are expressed as no. (%), or mean (standard deviation, SD) as appropriate
Significant differences are marked by * (P < 0.05) or ** (P < 0.01)
of APACHE II score, Sequential Organ Failure Assessment (SOFA) score, suPAR, procalcitonin (PCT) and lactic acid compared with patients with sepsis. In addition, there were 19 patients (13.87 %) receiving mechanical ventilation treatment, 23 patients (16.79 %) receiving continuous renal replacement therapy, and 17 patients (12.41 %) receiving vasopressor support. There were significant differences in the proportion of patients receiving mechanical ventilation, continuous renal replacement therapy or vasopressor support among the three groups (Table 1).

**Kinetics of suPAR**

Among the enrolled patients, a total of 117 patients survived and 20 died. As shown in Fig. 1a, patients who died had significantly higher suPAR concentrations (15.82 ± 2.72 ng/mL) on admission in comparison with the survivors (9.04 ± 3.41 ng/mL, \(P < 0.01\)). To investigate whether plasma suPAR concentrations remain constant over time, serial plasma determinations were further conducted on day 3 and day 7 after admission. At each indicated day of sampling, plasma suPAR concentrations were markedly higher among non-survivors than among survivors. Plasma suPAR concentrations remained stable separately within survivors and within non-survivors during the first week of the disease course. In addition, in the septic shock group 14 patients died and 18 survived. These non-survivors had significantly higher suPAR concentrations (17.05 ± 2.96 ng/mL) on admission when compared with the survivors (10.48 ± 1.86 ng/mL, \(P < 0.01\)) in the septic shock group (Fig. 1b).

**Value of indicators in predicting poor outcome**

ROC analysis was constructed to examine the performance of indicators as predictors of poor outcome, and the area under the curve (AUC) for each indicator was calculated, respectively. The AUC, optimal cutoff value, sensitivity and specificity of each indicator are presented in Table 2. ROC curves indicated that suPAR had a strong power for predicting unfavorable outcome as suggested by AUC of 0.788 ± 0.058, which was less than that of APACHE II score (0.813 ± 0.055, \(P < 0.05\)) but greater than that of SOFA score (0.779 ± 0.075, \(P < 0.05\)) and PCT (0.651 ± 0.081, \(P < 0.01\)) (Fig. 2). Coordinate points of ROCs indicated that an APACHE II score of at least 15 as a cutoff had a specificity of greater than 70 % to predict death and suPAR of at least 10.82 ng/mL showed a specificity of greater than 70 % to predict death.

Furthermore, ROC analysis of the combination of APACHE II score and suPAR was further performed. We found that the AUCs were greater for the combination of APACHE II score and suPAR (0.878 ± 0.042) than for the single APACHE II score or single suPAR (Fig. 3), demonstrating that combination of APACHE II score and suPAR may supply the more powerful prognostic utility for the mortality of sepsis.

**Univariate Cox regression analysis**

We performed univariate Cox regression analysis to examine the associations of each variable with unfavorable outcome and calculated the standardized regression coefficient (\(\beta\)) and the HR for each variable. As shown in Table 3, baseline APACHE II score had the greatest absolute value of standardized \(\beta\) value (0.2457). The absolute value of standardized \(\beta\) value for suPAR was 0.1482 and the unadjusted HR was 2.18 (95 % confidence interval [CI], 1.77-2.95, \(P = 0.000\)), indicating that suPAR had a power for predicting unfavorable outcome.

**Multivariate Cox regression analysis**

A multivariate Cox regression analysis was conducted using a forward step-wise manner to determine a novel risk stratification rule. All the observed baseline parameters like age, gender, lactic acid, blood urea nitrogen, serum creatinine, APACHE II score, SOFA score, suPAR...
and PCT were included in the prediction model when advent of death was set as the dependent variable. The results are shown in Table 4. According to this analysis, APACHE II score of at least 15 and plasma suPAR concentrations of at least 10.82 ng/mL were the independent predictors which entered the equation, demonstrating that these above defined cutoff values may be safely used to create a stratification rule for evaluating unfavorable outcome in sepsis.

The prognostic significance of suPAR was further confirmed after the risk stratification rule was generated (Table 5). More precisely, OR for death with suPAR of at least 10.82 ng/mL among patients with an APACHE II score of less than 15 was 4.72; OR was 2.04 with suPAR of at least 10.82 ng/mL among patients with an APACHE II score of at least 15. The calculated ORs were significantly different, demonstrating that APACHE II score and suPAR were independently associated with the unfavorable outcome and could both be integrated into a risk stratification rule.

**Risk stratification rule of APACHE II score and suPAR**

On the basis of the above cutoffs of APACHE II score and suPAR, risk stratification rule was determined as follows: (A) patients with an APACHE II score of less than 15 and suPAR of less than 10.82 ng/mL, (B) patients with an APACHE II score of less than 15 and suPAR of at least 10.82 ng/mL, (C) patients with an APACHE II score of at least 15 and suPAR of less than 10.82 ng/mL, and (D) patients with an APACHE II score of at least 15 and suPAR of at least 10.82 ng/mL. There were 72, 27, 18, and 20 patients in each stratum, with respective mortalities of 1.39 % ($n = 1$), 11.11 % ($n = 3$), 27.78 % ($n = 5$), and 55.0 % ($n = 11$). As show in Fig. 4, each stratum differed significantly from the others ($P = 0.002$ by the log-rank test within the defined strata). This prediction score corresponded to different grades of disease severity,

**Table 2** Performance of variables in predicting unfavorable outcome

| Variables          | AUC ROC          | P value       | Cutoff value | Sensitivity (%) | Specificity (%) |
|--------------------|------------------|---------------|--------------|-----------------|-----------------|
| APACHE II score    | 0.813 ± 0.055    | <0.001**      | ≥15.00       | 89.6            | 74.8            |
| SOFA score         | 0.779 ± 0.075    | <0.001**      | ≥8.50        | 80.7            | 72.1            |
| suPAR              | 0.788 ± 0.058    | <0.001**      | ≥10.82       | 84.9            | 77.6            |
| PCT                | 0.651 ± 0.081    | 0.078         | ≥24.97       | 57.5            | 69.2            |

Abbreviations: *AUC ROC area under the receiver operating characteristic curve, APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA sequential organ failure assessment, suPAR soluble urokinase plasminogen activator receptor, PCT procalcitonin*

Significant differences are marked by **($P < 0.01$)**

---

**Fig. 2** Receiver operating characteristic (ROC) curves of suPAR, PCT, APACHE II score, and SOFA score on day 1. suPAR had a strong power for predicting unfavorable outcome as suggested by area under the curve (AUC) of $0.788 \pm 0.058$, $P = 0.001$. suPAR, soluble urokinase plasminogen activator receptor; PCT, procalcitonin; APACHE II, Acute Physiology and Chronic Health Evaluation II; SOFA, Sequential Organ Failure Assessment
therefore patients with severe sepsis/septic shock tended to have score levels (C) and (D) when patients with sepsis tended to have score levels (A) and (B).

Discussion
Undoubtedly, APACHE II score has been advocated as the gold standard for risk evaluation in critically ill patients [19]. Nevertheless, a growing body of evidence has suggested that the score may supply inaccurate information in the certain patients, such as disproportionately high scores in patients who are loss of consciousness [20]. This translates into a real-world context in which the efficacy of APACHE II score to predict death is not as powerful as clinicians would consider.

To our knowledge, previous study conducted by Giamarellos-Bourboulis et al. has proposed a new prognostication rule for predicting the outcome of sepsis by APACHE II score and suPAR [5]. Our study was to further reaffirm the risk stratification system for Chinese patients with sepsis by combining APACHE II score and plasma suPAR concentrations. There were some differences between our study and Giamarellos-Bourboulis’s study. First, the enrolled patients of the two studies were from different ethnic groups. We enrolled Asian populations (Chinese origin), while Giamarellos-Bourboulis et al. mainly enrolled the European populations. Second, the cutoffs of APACHE II and suPAR which were used to determine the strata of disease severity were not uniformly the same. Specifically, our study indicated that

**Table 3** Predictors of unfavorable outcome by univariate Cox regression analysis

| Variables     | Standard β | Hazard ratio | 95 % CI | P value |
|---------------|------------|--------------|---------|---------|
| Age           | 0.0083     | 1.07         | 0.94–1.50 | 0.634   |
| Gender        | 0.0815     | 1.34         | 0.91–1.83 | 0.759   |
| Lactic acid   | 0.0368     | 1.02         | 0.82–1.15 | 0.332   |
| BUN           | 0.0240     | 1.01         | 0.57–1.12 | 0.458   |
| Scr           | 0.0217     | 1.00         | 0.53–1.04 | 0.465   |
| APACHE II score | 0.2457   | 3.01         | 2.26–4.69 | <0.001** |
| SOFA score    | 0.1243     | 1.68         | 1.14–2.39 | <0.001** |
| SuPAR         | 0.1482     | 2.18         | 1.77–2.95 | <0.001** |
| PCT           | 0.0891     | 1.67         | 1.42–2.08 | 0.024*   |

**Table 4** Independent predictors of unfavorable outcome by multivariate Cox regression analysis

| Variables     | Standard β | Hazard ratio | 95 % CI | P value |
|---------------|------------|--------------|---------|---------|
| APACHE II score | 0.2743   | 3.57         | 2.38–4.40 | <0.001** |
| SuPAR         | 0.1530     | 2.26         | 1.94–2.87 | <0.001** |

Abbreviations: BUN blood urea nitrogen, Scr serum creatinine, APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA sequential organ failure assessment, suPAR soluble urokinase plasminogen activator receptor, PCT procalcitonin, CI confidence interval

The hazard ratio indicates the risk of obtaining unfavorable outcome

Significant differences are marked by * (P < 0.05) or ** (P < 0.01)
APACHE II ≥15 and suPAR ≥10.82 ng/mL were independently associated with unfavorable outcome while Giamarellos-Bourboulis’s study showed that APACHE II ≥17 and suPAR ≥12 ng/ml were the optimal cutoffs. Third, we constructed ROC analysis and calculated the AUC to compare the performance of suPAR, PCT, APACHE II score, and SOFA score as predictors of poor outcome. We found that suPAR had a strong power for predicting unfavorable outcome as suggested by AUC of 0.788 ± 0.058, which was less than that of APACHE II score (0.813 ± 0.055) but greater than that of SOFA score (0.779 ± 0.075) and PCT (0.651 ± 0.081). However, Giamarellos-Bourboulis et al. just conducted ROC analysis with suPAR and APACHE II score as independent variables to predict unfavorable outcome. Taken together, given enrolled patients were from different ethnic groups, our study may further confirm the preliminary conclusion that a prediction rule with four levels of risk in sepsis based on APACHE II score and suPAR was proposed.

Similar to the findings of a previous clinical trial concerning plasma suPAR measurement [15], our study clearly showed that suPAR concentrations were relatively stable in the systemic circulation in both survivors and non-survivors during the first week of the disease course. Therefore, we infer that the validity of the developed prognostication score remains constant even if suPAR is not measured during the very first days after ICU admission due to the stability of suPAR concentrations over the disease course. These findings were comparable to other diseases including chronic obstructive pulmonary disease (COPD) [21] or acute respiratory distress syndrome (ARDS) [22], in which suPAR was regarded as an independent predictor for unfavorable outcomes.

Severe sepsis has a reported annual incidence in adults of up to 300 cases per 100,000 population [23, 24]. Affected patients have high mortalities, complications, and resource utilization. Although figures have improved in the recent years [2, 3], the risk for death remains high [25]. Consequently, improving outcome may be a daunting work. One of pivotal measures is to identify the septic patients with poor prognosis rapidly [4]. Our study suggested one composite rule for determining patients with sepsis at high risk on the basis of APACHE II score and plasma suPAR concentrations. Actually, the measurement procedure is so simple that we can complete the measurement for every 45 patient samples within about 4 h. The price for the measurement is also relatively reasonable and we only spend 6,000 CNY (about 924 USD) on evaluating 45 patient samples, that means we need spend about 133 CNY (20 USD) on measuring

**Table 5** Validation of the novel stratification rule

| APACHE II score | suPAR | Survivors, Number (%) | Non-survivors, Number (%) | P value | OR (95% CI) |
|-----------------|-------|------------------------|---------------------------|---------|------------|
| <15             | <10.82| 71 (98.61%)            | 1 (1.39%)                 | <0.001**| 4.72 (3.36–5.81) |
| ≥10.82          |       | 24 (88.89%)            | 3 (11.11%)                |         |            |
| ≥15             | <10.82| 13 (72.22%)            | 5 (27.78%)                | <0.001**| 2.04 (1.85–3.50) |
| ≥10.82          |       | 9 (45.00%)             | 11 (55.00%)               |         |            |

Abbreviations: APACHE II Acute Physiology and Chronic Health Evaluation II, suPAR soluble urokinase plasminogen activator receptor, OR odds ratio, CI confidence interval

The OR indicates the risk of obtaining unfavorable outcome

Significant differences are marked by **(P < 0.01)
one patient sample. Undoubtedly, the suPAR measurement is relatively cost-effective. Therefore, given the simple and inexpensive measurement, the combination of APACHE II score and plasma suPAR concentrations may contribute to intensive care management in the septic patients properly.

Currently, evidence has suggested that the value of single scoring system as a standard of clinical decision-making in septic patients is questionable. APACHE II score is likely to recognize either low-risk patients or very-high-risk patients, but not these patients between the two extremes [20]. The proposed risk stratification rule fulfills this need because it discriminates not only patients lying at one of the two extremes - strata (A) and (D) - but also patients with moderate disease severity, namely patients with an APACHE II score of less than 15 and suPAR of at least 10.82 ng/mL or patients with an APACHE II score of at least 15 and suPAR of less than 10.82 ng/mL, who belong to strata (B) and (C), respectively.

Conclusions
In summary, combination of APACHE II score and suPAR may supply the powerful prognostic utility for the mortality of sepsis. Our findings suggest that incorporating suPAR into APACHE II score as a composite risk stratification rule for suPAR is worth considering.

Abbreviations
APACHE II, Acute Physiology and Chronic Health Evaluation II; ARDS, acute respiratory distress syndrome; AUC, area under the curve; CI, confidence interval; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; IQR, interquartile ranges; OR, odds ratio; PCT, procalcitonin; ROC, receiver operating characteristics; SD, standard deviation; SOFA, sequential organ failure assessment; suPAR, soluble urokinase plasminogen activator receptor; uPA, urokinase plasminogen activator; uPAR, urokinase plasminogen activator receptor

Acknowledgements
None.

Funding
This work was financially supported by the grant from the 2013-2014 National Clinical Key Specialty Construction Project.

Availability of data and materials
All datasets are presented in the main paper or additional supporting files.

Authors’ contributions
XL and SP have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; XL, YS, and ZL have been involved in drafting the manuscript or revising it critically for important intellectual content; AF and HW have given final approval of the version to be published; QG and SP have agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
The study was approved by Shanghai Jiaotong University Xinhua Hospital Ethics Committee and was carried out in accordance with the Declaration of Helsinki. Informed consents were obtained from all patients.

Received: 12 January 2016 Accepted: 15 July 2016
Published online: 29 July 2016

References
1. ARSE Investigators; ANZICS Clinical Trials Group, Peake SL, Delaney A, Bailey M, Bellomo R, Cameron PA, Cooper DJ, Higgins AM, Holdgate A, Howe BD, et al. Goal-directed resuscitation for patients with early septic shock. N Engl J Med. 2014;371:1496–506.
2. Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000–2012. JAMA. 2014;311:1308–16.
3. Reinhart K, Daniels R, Kissoon N, O’Brien J, Machado FR, Jimenez E, GSA Executive Board and WSD Executive Board. The burden of sepsis-a call to action in support of World Sepsis Day 2013. J Crit Care. 2013;28:526–8.
4. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock, 2012. Critical Care Med. 2013;39:165–228.
5. Giannarellos-Bourboulis EJ, Norrby-Teglund A, Mylona V, Savva A, Tsangaris I, Dimitropoulou I, Mouktaroudi M, Raftogiannis M, Georgiopoulou D, Linnér A, et al. Risk assessment in sepsis: new prognostication rule by APACHE II score and serum soluble urokinase-plasminogen activator receptor. Crit Care. 2012;16:R49.
6. Vera S, Martínez R, Gormaz JG, Gajardo A, Galleguillos F, Rodrigo R. Novel relationships between oxidative stress and angiogenesis-related factors in sepsis: New biomarkers and therapies. Ann Med. 2015;47:289–300.
7. Hong DY, Kim JW, Paik JH, Jung HM, Baek KJ, Park SO, Lee KR. Value of plasma neutrophil gelatinase-associated lipocalin in predicting the mortality of patients with sepsis at the emergency department. Clin Chim Acta. 2015;452:177–81.
8. Linder A, Arnold R, Boyd JH, Zindovic M, Zindovic I, Lange A, Paulsson M, Nyberg P, Russell JA, Pitchard D, et al. Heparin-Binding Protein Measurement Improves the Prediction of Sepsis Mortality. Shock. 2015;44:414–7.
9. Munro M, Dunn J, Shergill JS, Broomfield D, Kwon S, Kalassy M, Block J, Bennett M, et al. A new marker for the prediction of sepsis in the emergency department. Clin Biochem. 2013;46:225–9.
17. Okulu E, Arsan S, Akin IM, Ates C, Alan S, Kilic A, Atasay B. Serum Levels of Soluble Urokinase Plasminogen Activator Receptor in Infants with Late-onset Sepsis. J Clin Lab Anal. 2015;29:347–52.

18. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med. 2003;31:1250–6.

19. Corrêa TD, Sanches PR, de Morais LC, Scarin FC, Silva E, Barbas CS. Performance of noninvasive ventilation in acute respiratory failure in critically ill patients: a prospective, observational, cohort study. BMC Pulm Med. 2015;15:144.

20. Vincent JL, Opal SM, Marshall JC. Ten reasons why we should NOT use severity scores as entry criteria for clinical trials or in our treatment decisions. Crit Care Med. 2010;38:283–7.

21. Can Ü, Güzelant A, Yerlikaya FH, Yosunkaya Ş. The role of serum soluble urokinase-type plasminogen activator receptor in stable chronic obstructive pulmonary disease. J Investig Med. 2014;62:938–43.

22. Geboers DG, de Beer FM, Tuip-de Boer AM, van der Poll T, Horn J, Cremer OL, Bonten MJ, Ong DS, Schultz MJ, Bos LD. Plasma suPAR as a prognostic biological marker for ICU mortality in ARDS patients. Intensive Care Med. 2015;41:1281–90.

23. Jawad I, Lukšić I, Rafnsson SB. Assessing available information on the burden of septic global estimates of incidence, prevalence and mortality. J Glob Health. 2012;2:010404.

24. Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med. 2013;41:1167–74.

25. Harrison DA, Welch CA, Eddleston JM. The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. Crit Care. 2006;10:R42.